Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke

Inclusion Criteria: * 1\. Age 18-80 years, regardless of gender. * 2\. Clinically diagnosed with acute ischemic stroke and meets the criteria for tenecteplase intravenous thrombolysis. * 3\. Onset of the current stroke within 4.5 hours. * 4\. Clinical diagnosis of minor ischemic stroke with a NIHSS score of 2-5, accompanied by persistent unilateral limb weakness or speech symptoms, defined as a score ≥1 on either the language item or any one limb item of the NIHSS * 5\. Pre-stroke mRS score ≤1. * 6\. The subject or their legal representative is able and willing to sign the informed consent form. Exclusion Criteria: * 1\. History of intracranial hemorrhage. * 2\. Patients who have received or plan to undergo mechanical thrombectomy. * 3\. History of major head trauma or stroke within the past 3 months. * 4\. Known severe liver/kidney dysfunction or patients receiving dialysis (severe liver dysfunction: ALT/AST \>3 times the upper limit of normal; severe kidney dysfunction: serum creatinine \>3.0 mg/dl \[265.2 μmol/L\] or GFR \<30 ml/min/1.73 m²). * 5\. Systolic blood pressure \<90 mmHg or \>220 mmHg. * 6\. Patients with bradycardia (heart rate \<60 beats/min) or sick sinus syndrome. * 7\. History of drug/food allergy or known allergy to the components of the study drugs. * 8\. Patients treated with drugs containing butylphthalide after stroke onset. * 9\. History of congenital/acquired hemorrhagic diseases, coagulation factor deficiency, or thrombocytopenic diseases. * 10\. Pregnant or lactating subjects or subjects planning to become pregnant within 90 days. * 11\. Subjects with severe mental disorders or dementia who cannot cooperate with informed consent and follow-up. * 12\. Subjects with concurrent malignant tumors or severe systemic diseases, with an expected survival of \<90 days. * 13\. Patients who have participated in other clinical interventional studies within 30 days prior to randomization, or who are currently participating in other clinical interventional studies; * 14\. Patients who are unable to complete follow-up visits as scheduled; * 15\. Any other reasons that, in the investigator's opinion, render the patient unsuitable for participation in the study.